CNTA Centessa Pharmaceuticals plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CNTA

Price (delayed)

$9.47

Market cap

$949.9M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.57

Enterprise value

$906.45M

Highlights
The company's EPS rose by 32% YoY and by 4.3% QoQ
The net income has grown by 30% YoY and by 4% from the previous quarter
Centessa Pharmaceuticals's quick ratio has decreased by 37% YoY and by 19% QoQ
CNTA's equity is down by 30% YoY and by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of CNTA
Market
Shares outstanding
100.31M
Market cap
$949.9M
Enterprise value
$906.45M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.91
Price to sales (P/S)
132.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
132.27
Earnings
Revenue
$6.85M
EBIT
-$166.24M
EBITDA
-$165.43M
Free cash flow
-$160.51M
Per share
EPS
-$1.57
Free cash flow per share
-$1.67
Book value per share
$2.42
Revenue per share
$0.07
TBVPS
$3.75
Balance sheet
Total assets
$360.25M
Total liabilities
$124M
Debt
$84.59M
Equity
$236.24M
Working capital
$275.71M
Liquidity
Debt to equity
0.36
Current ratio
8
Quick ratio
6.51
Net debt/EBITDA
0.26
Margins
EBITDA margin
-2,413.9%
Gross margin
100%
Net margin
-2,204.7%
Operating margin
-2,578.6%
Efficiency
Return on assets
-39.4%
Return on equity
-56.7%
Return on invested capital
-65%
Return on capital employed
-51.8%
Return on sales
-2,425.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CNTA stock price

How has the Centessa Pharmaceuticals stock price performed over time
Intraday
-0.84%
1 week
6.17%
1 month
-12.48%
1 year
118.2%
YTD
18.97%
QTD
-16.19%

Financial performance

How have Centessa Pharmaceuticals's revenue and profit performed over time
Revenue
$6.85M
Gross profit
$6.85M
Operating income
-$176.71M
Net income
-$151.09M
Gross margin
100%
Net margin
-2,204.7%
The net income has grown by 30% YoY and by 4% from the previous quarter
The operating income has grown by 16% YoY and by 3.1% from the previous quarter

Growth

What is Centessa Pharmaceuticals's growth rate over time

Valuation

What is Centessa Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.91
P/S
132.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
132.27
The company's EPS rose by 32% YoY and by 4.3% QoQ
CNTA's price to book (P/B) is 70% higher than its last 4 quarters average of 2.3
CNTA's equity is down by 30% YoY and by 9% QoQ

Efficiency

How efficient is Centessa Pharmaceuticals business performance
Centessa Pharmaceuticals's return on invested capital has surged by 77% YoY and by 23% QoQ
Centessa Pharmaceuticals's return on assets has increased by 8% YoY
The company's return on equity fell by 6% YoY and by 5% QoQ

Dividends

What is CNTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CNTA.

Financial health

How did Centessa Pharmaceuticals financials performed over time
CNTA's total assets is 191% greater than its total liabilities
Centessa Pharmaceuticals's quick ratio has decreased by 37% YoY and by 19% QoQ
CNTA's current ratio is down by 30% year-on-year and by 16% since the previous quarter
The debt is 64% smaller than the equity
Centessa Pharmaceuticals's debt to equity has surged by 71% YoY and by 13% QoQ
CNTA's equity is down by 30% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.